Bortezomib-induced painful neuropathy in rats: A behavioral, neurophysiological and pathological study in rats
详细信息 查看全文
- 作者：Cristina Meregalli ; Annalisa Canta ; Valentina A. Carozzi ; Alessia Chiorazzi ; Norberto Oggioni ; Aless ; ra Gilardini ; Cecilia Ceresa ; Federica Avezza ; Luca Crippa ; Paola Marmiroli ; Guido Cavaletti
- 关键词：Bortezomib ; Proteasome inhibitors ; Neuropathic pain ; Mechanical allodynia ; Axonopathy
- 刊名：European Journal of Pain
- 出版年：2010
- 出版时间：April 2010
- 年：2010
- 卷：14
- 期：4
- 页码：343-350
- 全文大小：832 K
文摘
Bortezomib is a proteasome inhibitor showing strong antitumor activity against many tumors, primarily multiple myeloma. Bortezomib-induced neuropathic pain is the main side effect and the dose-limiting factor of the drug in clinical practice. In order to obtain a pre-clinical model to reproduce the characteristic pain symptoms in bortezomib-treated patients, we developed an animal model of bortezomib-induced nociceptive sensory neuropathy. In this study, bortezomib (0.15 or 0.20 mg/kg) was administered to Wistar rats three times/week for 8 weeks, followed by a 4 week follow-up period. At the end of the treatment period a significant decrease in weight gain was observed in the treated groups vs. controls, and hematological and histopathological parameters were evaluated. After the treatment period, both doses of bortezomib induced a severe reduction in nerve conduction velocity and demonstrated a dose-cumulative effect of the drug. The sensory behavioral assessment showed the onset of mechanical allodynia, while no effect on thermal perception was observed.
Sciatic nerves and dorsal root ganglia (DRG) were collected at the end of the 8-week treatment and at the end of the follow-up period. The pathological examination revealed a dose-dependent axonopathy of the unmyelinated fibers in nerves of treated animals. No pathological alteration in most of DRG satellite cells and neurons was observed.
Therefore, this animal model may be useful for studying the neurotoxicity and pain onset mechanisms related to bortezomib treatment.